Immunodominant

Immunodominant Announces Call for Initial Investment Round as Company Prepares for Phase 2 Study of Oral OTC COVID-19 Drug

Immunodominant Inc., a drug discovery and development company engaged in progressing innovative research from academia to commercialization, today announced its intention to begin an initial financing round of up to $30 million. Immunodominant also announced today that it is scheduling a Phase 2 clinical study after a pre-IND meeting with the FDA for LACTOVID, a novel, oral, over-the-counter drug for the prevention and treatment of COVID-19. - November 20, 2022